ABUS - Arbutus Biopharma Corporation
| Previous Close | 4.3900 |
| Open | 4.3500 |
| Bid | 4.21 x 3200 |
| Ask | 4.58 x 900 |
| Day's Range | 4.3300 - 4.5900 |
| 52 Week Range | 4.0100 - 12.6000 |
| Volume | 214,073 |
| Avg. Volume | 390,566 |
| Market Cap | 243.09M |
| Beta (3Y Monthly) | 3.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.51 |
| Earnings Date | Mar 13, 2019 - Mar 20, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.32 |
- GlobeNewswire•5 days ago
New Research Coverage Highlights Nokia, SecureWorks, National Western Life Group, Brookfield Asset Management, FormFactor, and Arbutus Biopharma — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Insider Monkey•7 days ago
Is PennyMac Financial Services Inc (PFSI) A Good Stock To Buy?
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
- Simply Wall St.•11 days ago
Why Arbutus Biopharma Corporation’s (NASDAQ:ABUS) CEO Pay Matters To You
Mark Murray became the CEO of Arbutus Biopharma Corporation (NASDAQ:ABUS) in 2008. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
- GlobeNewswire•19 days ago
Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been appointed as Chairman of the Company’s Board of Directors, effective November 26, 2018. “We are pleased to welcome Frank to our Board,” said Dr. Mark J Murray, President and CEO of Arbutus. For much of his career, Dr. Torti was a partner at New Enterprise Associates (NEA), a leading venture capital firm.
- Zacks•25 days ago
Options Traders Expect Huge Moves in Arbutus (ABUS) Stock
Arbutus (ABUS) needs investors to pay close attention to the stock based on moves in the options market lately.
- GlobeNewswire•last month
Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug.
- GlobeNewswire•2 months ago
Arbutus to Report Third Quarter 2018 Financial Results
WARMINSTER, Pa., Oct. 31, 2018 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- GlobeNewswire•2 months ago
Arbutus Names New Members to its Board of Directors
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James Meyers and Myrtle Potter have been appointed to the Arbutus Board of Directors, effective October 18, 2018, replacing Herbert Conrad and Dr. William Symonds. Dr. Symonds will remain with Arbutus as Chairman of its Clinical Advisory Board.
- GlobeNewswire•2 months ago
New Research Coverage Highlights Arbutus Biopharma, Tata Motors, Core-Mark Holding, Tenaris S.A, Addus HomeCare, and ZTO Express (Cayman) — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•2 months ago
What Kind Of Risk Should You Expect For Arbutus Biopharma Corporation (NASDAQ:ABUS)?
If you’re interested in Arbutus Biopharma Corporation (NASDAQ:ABUS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
- Zacks•2 months ago
Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Arbutus Biopharma and Akcea Therapeutics
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial ...
Market Realist•2 months agoWhy Arbutus Biopharma Stock Plunged 24.4% Today
Today, Arbutus Biopharma (ABUS) stock is trading at $6.87, which is a 24.42% decline from its October 8 closing price of $9.09. Arbutus Biopharma’s closing price on October 8 represents ~111.0% growth from its 52-week low of $4.30 on December 15, 2017. On August 2, Arbutus Pharma hit its 52-week high of $12.60.
- Motley Fool•2 months ago
Here's Why Arbutus Biopharma Corp. Is Tanking Today
The clinical-stage biotech reported good news and bad news -- with the bad outweighing the good.
- GlobeNewswire•2 months ago
Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
AB-506, the Company’s second generation capsid inhibitor, has progressed through the healthy volunteer portion of a multi-component phase 1a/1b study in which it was demonstrated to be generally safe and well-tolerated after 10 days of dosing. This month, AB-506 will enter the 28-day HBV patient portion of the trial, where it will be evaluated both with and without a nucleoside analog.
- GlobeNewswire•2 months ago
Arbutus to Present at Chardan’s Genetic Medicines Conference
WARMINSTER, Pa., Oct. 02, 2018 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that.
- Zacks•3 months ago
Are Options Traders Betting on a Big Move in Arbutus (ABUS) Stock?
Investors need to pay close attention to Arbutus (ABUS) stock based on the movements in the options market lately.
Market Realist•3 months agoWhy Dicerna Pharmaceuticals Stock Rose 7.7% Yesterday
On September 13, Dicerna Pharmaceuticals (DRNA) stock rose 7.71% to $16.62 from its previous day’s close of $15.43. In the trial, Dicerna’s lead drug candidate, DCR-PHXC, showed that it was capable of bringing urinary oxalate levels to a normal or near-normal range in individuals with primary hyperoxaluria type 1 and hyperoxaluria type 2. The company is conducting studies with DCR-PHXC and investigating its potential as a therapy for all forms of hyperoxaluria.
Market Realist•3 months agoWhy Arrowhead Pharmaceuticals Stock Is Skyrocketing Today
Today, Arrowhead Pharmaceuticals (ARWR) stock is trading at $20.12, which represents ~42.7% growth from yesterday’s close of $14.10. Arrowhead Pharmaceuticals also hit its 52-week high of $22.39 today.
- ACCESSWIRE•4 months ago
Arbutus Biopharma Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Arbutus Biopharma Corporation (NASDAQ: ABUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...
